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survey was developed for patients (adults/children) and caregivers. Patients were 
recruited by patient organisations in cystic fibrosis (CF), Prader–Willi syndrome 
(PWS), haemophilia (HEMO), Duchenne muscular dystrophy (DMD), epidermolysis 
bullosa (EB), fragile X syndrome (FXS), scleroderma (SCL), mucopolysaccharidosis 
(MPS), juvenile idiopathic arthritis (JIA) and histiocytosis (HIS). Demography amd 
main characteristics were recorded. Patients’ and caregivers’ health state was 
assessed by the EQ-5D-5L, disability and caregivers’ burden by the Barthel Index 
and Zarit Burden Interview questionnaires. Results: In Hungary, 296 Hungarian 
patients (children: 161, 54%) participated in the study (CF 110, PWS 5, HEMO 58, 
DMD 57, EB 6, FXS 12, SCL 38 and MPS 10 patients), no data were obtained in JIA and 
HIS. Mean age among adults/children was 37.0 (SD 16.1) / 9.6 (SD= 4.5) years, and 
disease duration was 18.5 (SD= 14.4) / 7.1 (SD= 4.5) years, respectively. The lowest 
average EQ-5D-5L score was found in MPS (0.134 / 0.070) and DMD (0.310 / 0.198) 
just alike with the Barthel Index (MPS: 35.6; DMD 58.0). Caregivers’ (N= 95) mean 
age was 39.2 (SD= 8.0) years and their EQ-5D-5L score (0.797, SD= 0.251) was not sig-
nificantly different from the general populations’ average. Satisfaction with health 
care (1-10 Likert scale) was the lowest in MPS, DMD and EB (mean 4.1, 5.2 and 
4.3). ConClusions: Rare diseases induce substantial deterioration of patients’ 
quality of life and impose burden on caregivers. Taking an integrated approach our 
results can serve for international comparisons and facilitate further investigations 
in other orphan diseases.
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objeCtives: The aim of the UK multi-centre LupusQoL Sensitivity Study is to 
assess whether the LupusQoL, a systemic lupus erythematosus (SLE) specific, 
health-related quality of life measure is sensitive to change when disease activ-
ity improves or deteriorates. Methods: Patients with SLE experiencing a flare 
(baseline) & requiring an increase in treatment were recruited. Assessments were 
undertaken at baseline & monthly for 9 months & included BILAG-2004 disease 
activity index & the LupusQoL with 8 domains and scores ranging from 0 (worst) 
to 100 (best HRQoL). LupusQoL domain scores when disease activity improved or 
deteriorated between consecutive time-points are reported as mean changes, with 
95% CI constructed using robust standard errors to account for repeated patient 
assessments. Results: Mean (SD) age was 40.9 (12.8) & duration since diagno-
sis was 9.3 (8.1) years for the 101 patients recruited; 94% females, 62.6% white 
Caucasians. At baseline all mean LupusQoL domain scores were < 52. Scores for 
LupusQoL physical health (+4.0, 95%CI 1.9 to 6.1), pain (+7.7, 95%CI 4.8 to 10.5) & 
fatigue (+4.1, 95%CI 1.7 to 6.5) increased when BILAG improved. Scores for physi-
cal health (-4.9, 95% -9.4 to -0.4) and pain (-6.9, 95%CI -12.9 to -0.8) decreased with 
a major BILAG deterioration but changes with a minor deterioration were small 
and non-significant. The effects of improvements & deterioration in BILAG on 
the other LupusQoL domain scores were smaller. ConClusions: Improvement 
and deterioration of LupusQoL domain scores for physical health, pain & fatigue 
domain scores was seen in patients with significant changes in disease activity 
over 1 month. Sensitivity to change of other LupusQoL domains in relation to 
changes in disease activity may need to be evaluated over a longer interval as the 
more emotive type of response to the disease & its consequences may be latent 
and therefore not evident at monthly intervals.
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objeCtives: To assess the Quality of Life (QoL), focusing on level of pain, of patients 
submitted to surgical interventions with robotic technique in comparison with 
traditional approach in the Italian setting. Methods: The prospective multicen-
tre study analysed the QoL of 699 patients submitted to surgical interventions, 
enrolled in 8 Italian Hospitals for the period February 2011-May 2014. The specialties 
were general, thoracic, gynecological surgery performed with open, manual lapa-
roscopic or robotic technique. Patients completed two questionnaires: one related 
to pain intensity during the hospitalization and one fulfilled at home related to 
pain intensity and its impact on daily activities, mood, relationship, sleep. Pain was 
measured using the scale of facial expressions corresponding to the Visual Analog 
Scale. For each intervention and specialty, linear regression for repeated measure, 
corrected by length of stay and use of analgesics, were performed to explain level 
of pain during hospitalization and at home, respectively. Results: Level of pain 
during hospitalization is significantly (p= 0.05) lower in general and gynecological 
robotic surgery versus the open technique, but not versus laparoscopic, while robotic 
thoracic surgery presents significant differences with laparoscopic but not with 
open surgery (p= 0.059). Level of pain at home is significantly different for robotic 
interventions versus open both in general and gynecological surgery; moreover, 
with respect to laparoscopic interventions, the differences are significant both in 
gynecological and in thoracic but not in general surgery. ConClusions: The study 
gives us insightful knowledge about QoL, focusing on pain, of patients submitted to 
surgical interventions with robotic technique vs traditional surgery. Further analysis 
are in progress to combine results on QoL, not only referred to level of pain, with 
clinical severity and other indicators of clinical efficacy as length of stay, operating 
hemophilic joint health (0.67vs. 0.73, p< .001) or disability (0.65 vs. 0.70, p< .001) as 
similar as in the results of Haemo-QoL. With patients who were either on a job or 
students (n= 467, 77.2%), LPT was estimated at 127.81 hours per month on average. 
Of 467, patients with inhibitor or disability showed higher LPT compared to those 
without inhibitor (130.61 vs. 126.61 hours per month, p= 0.486) or disability. (132.27 
vs. 124.95 hours per month p=.087). ConClusions: The study findings suggest that 
patients’ clinical characteristics should take into account for the management of 
hemophilia given patient-reported outcomes differed by clinical manifestations.
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objeCtives: To assess the burden of LN in comparison to SLE patients without 
Nephritis (Non-LN) in routine clinical practices in EU. Methods: A multi-center 
medical chart-review of adult (16-89yrs) SLE patients was conducted among rheu-
matologists and internal medicine physicians in UK/France/Germany/Italy/Spain 
(5EU). Physicians were recruited from a geographically representative sample in 
each country. Approx. 5 consecutive eligible persistent active or relapse remitting 
SLE patients currently managed as part of usual care were identified. Physicians 
abstracted de-identified patient data on disease characteristics, lab values and 
treatment patterns. LN and Non-LN cohorts were compared using descriptive 
statistics. Results: 168 LN patients and 569 non-LN patients with SLE were ana-
lyzed. Patient characteristics included (LN/Non-LN): age (yrs): 40.2/42.7; % Female: 
82.7/79.4; % Caucasian: 82.7%/88.8%; % full-time employment: 32.1/36.0; % part-time 
employment: 19.0%/22.0%. Among LN/Non-LN cohorts, frequency of clinic visits was: 
9.5wks/10.6wks, % currently receiving care in in-patient setting was: 14.9/8.8, % hos-
pitalized > = 1 in the past-year was: 49.4/29.7; mean # of organ manifestations was: 
3.9/3.0. Top-5 organ manifestations were (% LN/Non-LN): musculoskeletal: 85.1/90.8, 
mucocutaneous: 85.1/84.8, haematologic: 51.8/52.2, renal: 100.0/5.9, pulmonary: 
16.7/16.2; % experiencing a flare was (LN/Non-LN): 23.2/16.6. Renal biopsy was per-
formed in 87.5% (LN) and 4.0% (Non-LN) of patients. Steroids were used by 82.1% 
(LN) and 69.4% (Non-LN). % patients with low C3 and C4 was LN: 66.3/48.1/Non-LN: 
60.2/50.0; mean ESR scores were 40.2 (LN) and 36.8 (Non-LN). Among patients with 
available data, SELENA-SLEDAI scores were 11.5 (LN) and 8.5 (Non-LN). Humanistic 
burden (reported via physician ratings, on a scale of 0 (most impact) to 7 (least impact)) 
was (LN/Non-LN, mean scores): ability to perform every-day tasks: 5.0/5.3, ability to 
interact fully with family and friends: 5.4/5.6, and ability to work/keep employment: 
4.5/5.0. ConClusions: LN cohorts had higher clinical and humanistic burden in 5EU 
in comparison to their non-LN SLE counterparts. Factors influencing the observed 
burden, including the therapeutic strategies used in these geographies warrant fur-
ther investigation to manage SLE, and LN in particular, optimally.
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objeCtives: To qualitatively assess the impact of Psoriasis on patient 
QoL. Methods: An ethnographic study with moderate/severe Psoriasis patients 
was conducted in 4EU (UK/France/Spain/Italy) and the US to explore patients’ views 
on treatment options and Psoriasis impact on QoL. Anthropologists and ethnog-
raphers spent several-hours with consented patients and filmed their behaviours 
inside and outside their homes in everyday situations. 175 hours of recordings/notes 
were analysed to identify QoL-related themes: self-image, psychological effects of 
psoriasis (e. g., anxiety/depression), life-style changes due to Psoriasis, relationship 
with family, friends and colleagues. Results: Study included 35 adult patients (4EU: 
20, US: 15; mean age: 39 yrs; female: 65%). Patients described their appearance with 
a sense of disgust and self-loathing. Feelings of frustration were often expressed due 
to a perceived lack of control of their lives. Prior to biologic initiation, daily rituals 
absorbed good part of their day, including waking up earlier to apply creams, going 
to work earlier to check their appearance and cover patches of dead skin. Due to 
lack of cultural discourse and patient’s difficulty in articulating Psoriasis’ impact, 
partners and family did not know how to react nor did they realize the full extent 
of the problem. Difficulty in getting appropriate psychological support needed left 
them with a feeling of resignation. As a result, majority dealt with their issues in 
isolation. Most patients experienced social discriminations due to Psoriasis which 
led some to lie about their disease, keeping it a secret. Biologic experienced patients 
noticed a significant improvement physically, but psychological scarring remained. 
Despite their regained confidence owing to the effectiveness of biologics, they still 
did not discuss their condition with family and friends. ConClusions: Patients 
with Psoriasis experienced significantly lower quality of life and high psychological 
scarring. Ethnographic study design vividly depicted the unarticulated and emo-
tional impact of Psoriasis on patients’ everyday lives.
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objeCtives: The Social Economic Burden and Health-Related Quality of Life in 
Patients with Rare Diseases in Europe (BURQOL-RD, http://www.burqol-rd.com/) 
project aimed to investigate disease burden and self-percieved health outcomes of 
patients and their caregivers in rare diseases in eight EU countries (Bulgaria, France, 
Germany, Hungary, Italy, Sweden, Spain, UK). Methods: An online questionnaire 
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of 16 criteria. Methods: 85 experts were interviewed to estimate the importance 
of each criterion in the decision-making on financing MT for rare diseases. We 
used 10-point scale, where 10 points mean major importance to the priority indica-
tor, and 1point means minor importance. Mean estimates were calculated using 
descriptive statistics, then means were normalized. Results: Respondents were 
41 years on average (ranging from 23 to 64 years), and included 20 public servants, 
16 health administrators, 32 practitioners, and 14 researchers. 44 respondents had 
a scientific degree. The most important criteria were characteristics of treatment - 
“Effect of treatment on quality of life” and “Effect of treatment on life expectancy” 
with 1 points each. The least important criteria were both characteristics of the 
disease - “Cognitive disorders as manifestations of the disease and “Additional bur-
den on the daily lives of care-givers” with 0.28 and 0.1 respectively. ConClusions: 
Characteristics of treatment turned out to be more important for respondents than 
characteristics of disease, therefore characteristics of treatment should be given 
consideration when evaluating rare diseases to determine priority financing.
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objeCtives: Opioid analgesics are proven to be safe and effective in malignant or 
nonmalignant pains. The consumption trend of six opioids (Morphine, Codeine, 
Oxycodone, Fentanyl, Pethidine, and Methadone) in Islamic Republic of Iran 
assumed as an indicator for prescription pattern and is evaluated during five year 
period (2007-2011) as the aim of this study. Methods: The data of opioid analgesic 
consumption were collected from FDO (Food and Drug Organization) of Iran. The 
collected data were converted to DDD (Define Daily Dose) for each of six selected 
opioids in order to be compared accurately. Results: Overall consumption of opi-
oids was grown during the period of investigation. Putting six selected opioids into 
two groups – synthetic and non-synthetic -, the growth rate of synthetic ones are 
obviously higher than those of non-synthetics. Opioid analgesics consumption in 
2011 was shown to be 4 times more than the opioid consumption in 2007. The CAGR 
(Compound Average Growth Rate) between 2007-2011 were reported 111.27%, 33.11%, 
16.48%, 3.91%, 3.76%, and -41.63% for Oxycodone, Methadone, Fentanyl, Morphine, 
Pethidine and Codeine respectively. The growth rate of mentioned above opioids 
for the last year of investigation was reported 41.12%, 16.54%, 29.99%, -0.38%, 7.66%, 
23.67% respectively. ConClusions: Like other low consuming countries, consump-
tion of opioid analgesics in Iran is limited by means of different kinds of barriers. 
There are also parameters which set a specific orientation in opioid consumption. 
Analyzing this trend, results in defining the barriers and other parameters clearly.
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objeCtives: In Europe, orphan designation has been granted by European 
Medicines Agency since 2000. Molecules with orphan designation can benefit from 
a number of incentives to guarantee return on investment for manufacturers. Since 
introduction of orphan legislation, the number of Orphan Drugs (OD) has signifi-
cantly increased. In 2012, total OD sales reached 13% of the whole pharmaceutical 
market. This study aims to analyse current situation and trends in OD approv-
als. Methods: All ODs approved gaining marketing authorization was identified 
through EMA website. Extensions to a new disease were considered as an independ-
ent approval, while extensions of indication for the same condition were not consid-
ered. Information on drug status, indications, therapeutic area, and authorisation 
date was extracted. Results: 77 orphan molecules were identified of which two 
have been withdrawn, and one orphan designation has expired. Yearly approvals 
continuously grow (from 2 ODs approved in 2002 to 12 and 8 drugs in 2012 and 2013 
respectively). By mid-2014, already 6 were approved. There is a high imbalance 
within therapeutic area with 36% for oncology, 27% for endocrine, nutritional and 
metabolic disorders whereas the remaining 37% cover 11 therapeutic classes. No 
product has been approved for 7 therapeutic areas despite existence of rare disor-
ders. Moreover, oncology is associated with the highest growth. ConClusions: 
Orphan drug market is rapidly growing but targeting selective therapeutic areas 
with high potential return on investment. The incentive policies happen to well 
function but discriminate among diseases. A review of orphan drug policies might 
be warranted to ensure patient equity in development of new OD.
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objeCtives: While there exist a number of incentives to stimulate research and 
development of orphan drugs (OD), the Health Technology Assessment (HTA) agen-
cies do not offer specific path for OD in most countries where it is left to payer value 
judgement. This leads to a high inequity in patient access to OD. The study aims 
at comparing the HTA decisions, price and reimbursement level of OD in France 
and Italy. Methods: All OD assessed since 2000 were analysed. Prices, reimburse-
ment rates and decision details were extracted for each drug using Farmadati Italia 
database for Italy and Transparency committee reports, AMELI’s national health 
insurance and Thériaque databases for France. Results: Among 74 OD approved in 
Europe 66 are available in Italy compared to 53 in France. All ODs available in France 
are officially available in Italy. The average delay between the market authorization 
and the price and reimbursement decision was about 16 and 17 months in France 
and Italy, respectively. In France all available drugs are 100% reimbursed through 
hospital, 36 molecules are available in retail pharmacy with reimbursement from 
time, medical/surgical complications to refine a robust measure of effectiveness 
useful to perform cost effectiveness analysis.
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objeCtives: To assess the characteristics of SLE patients currently on Remission 
(Group-1), currently with active disease but not experiencing a flare (Group-2) and 
those who are experiencing flares (Group-3) in Europe (EU). Methods: A multi-
center medical chart review of adult (16-89 yrs) SLE patients was conducted in 
1Q2014 among rheumatologists/internal medicine physicians in UK/France/
Germany/Italy/Spain (5EU). Physicians were recruited from a geographically repre-
sentative sample in each country. Approx. 5 consecutive eligible persistent active or 
relapse remitting SLE patients currently managed as part of usual care were identi-
fied. Physicians abstracted de-identified patient data on disease characteristics, lab 
values and treatment patterns. Patient disease status and humanistic burden was 
assessed by physician per clinical judgment & patient interaction. Results: 747 SLE 
patient charts were abstracted in 5EU (UK: 156/France: 149/Germany: 148/Italy: 146/
Spain: 148); Group-1: 25.7% (range: 19.9% (Italy) –29.7% (Germany)), Group-2: 56.2% 
(range: 42.3% (UK) –66.4% (Italy)), Group-3: 18.1% (range: 13.5 (Germany) –28.8 (UK)). 
Patient characteristics included (Group-1/Group-2/Group-3): age (yrs): 41.4/43/40.6; % 
female: 81.8/80.2/77.8; % full-time employment: 38.0/34.5/32.6; % part-time employ-
ment: 25.5/20.5/17.8; % on sick leave: 3.6/7.6/17.0; % currently receiving treatment 
in in-patient setting: 3.1/7.6/28.1; % hospitalized > = 1 in past-year: 23.4/32.1/55.6. 
Top-5 organ manifestations were (% Group-1/Group-2/Group-3): musculoskeletal: 
90.6/89.5/88.1, mucocutaneous: 86.5/84.0/85.2, haematologic: 45.8/53.8/55.6, renal: 
23.4/26.7/33.3, pulmonary: 15.1/13.6/26.7. In Group-1/Group-2/Group-3, % patients 
with low C3 and C4 were 33.3/53.9/73.4 and 31.6/53.2/77.5 and % anti-ds-DNA posi-
tive were 54.7/71.0/78.5. Humanistic burden (reported via physician ratings, on a 
scale of 0 (most impact) to 7 (least impact)) was (Group-1/Group-2/Group-3, mean 
scores): patient ability to perform every-day tasks: 6.11/5.17/4.37, patient ability to 
interact fully with family and friends: 6.20/5.45/4.90, and patient ability to work/
keep employment: 5.76/4.80/3.87. ConClusions: Over half of the SLE patients had 
an active disease while one-in-five were experiencing a flare in this study cohort, 
with significant variations observed within 5EU. Clinical and humanistic burden 
varied based on patient disease status, with highest burden observed among those 
experiencing flares.
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objeCtives: Despite increasing policy guidance to encourage the development 
of and access to orphan drugs, the policy landscape indicates a lack of transpar-
ency and consistency across countries. The objective of this study is to compare 
the orphan drug policies of Japan, South Korea, and Taiwan to the policies in the 
EU. Methods: A targeted literature review was conducted to identify papers per-
taining to orphan drugs in Japan, South Korea and Taiwan, with a focus on quantita-
tive analysis for policy-making related to pricing and reimbursement from the payer 
perspective. No limits were placed on language. Country specific policy websites 
were hand-searched. Results: A total of 3465 abstracts were identified for screen-
ing. Of those, 104 were eligible for full-text screening. The definition of prevalence 
with regard to rare diseases in Japan, South Korea and Taiwan was stricter than in 
the EU. All of them had introduced regulations, guidelines and incentives to the 
development of orphan-designated drugs. Strict HTA requirements were waived 
for rare diseases, although cost-effectiveness data are referenced in South Korea. 
In Japan and Taiwan, prices were reduced for existing drugs with new orphan-
designated indications. Within the existing benefits of national health insurance 
schemes or under the coverage of rare disease regulations, full reimbursement 
was given, which is different from the partial reimbursements observed in cer-
tain European countries. In some cases, the application of drug treatment can be 
approved prior to or without market authorisation. The availability of orphan drugs 
to patients was not inferior to that of the EU. ConClusions: While access in Japan, 
South Korea and Taiwan is seemingly no different to the EU, there are no consistent 
or transparent policies in place in these countries. Policy makers should prepare 
innovative schemes that offer warranties to both payers and patients and establish 
a systematic evaluation procedure for manufacturers.
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objeCtives: The ranking and prioritization of rare diseases are crucial in order to 
define for which of them state support measures are justifiable. For this purpose the 
set of 16 criteria to assess rare diseases (8 related to the characteristics of disease, 
and 8 to the characteristics of treatment) was proposed by experts, so multi-criteria 
decision (MCDA) analysis approach could be useful. The aim of the study was to 
assess the reliability of the criteria set and to determine the relative importance 
